Baseline and follow-up laboratory monitoring of cardiovascular medications;Monitoreo de laboratorios al inicio y en el seguimiento de medicamentos cardiovasculares

Annals of Pharmacotherapy

Volumn 45, Issue 9, 2011, Pages 1077-1084

  Tjia, Jennifer ^a   Fischer, Shira H ^b   Raebel, Marsha A ^c   Peterson, Daniel ^d   Zhao, Yanfang ^d   Gagne, Shawn J ^d   Gurwitz, Jerry H ^b   Field, Terry S ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United Kingdom)

^c KAISER PERMANENTE   (United States)

^d Meyers Primary Care Institute   (United Kingdom)

Author keywords

Boxed warning; Cardiovascular drugs; Laboratory monitoring; Patient safety; Physician behavior; Quality of care

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GEMFIBROZIL; LOOP DIURETIC AGENT; NICOTINIC ACID; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG LABELING; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; YOUNG ADULT;

EID: 80052493257     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q158     Document Type: Article

References (36)

1. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-64. DOI 10.1056/NEJMsa020703
2. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16 DOI 10.1001/jama.289.9.1107
3. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med 2005;20:1120-6 DOI 10.1111/j.1525-1497.2005.0257.x
4. Feldstein AC, Smith DH, Perrin N, et al. Improved therapeutic monitoring with several interventions: a randomized trial. Arch Intern Med 2006;166:1848-54 DOI 10.1001/archinte.166.17.1848
5. Palen TE, Raebel M, Lyons E, Magid DM. Evaluation of laboratory monitoring alerts within a computerized physician order entry system for medication orders. Am J Manag Care 2006;12:389-95.
6. Raebel MA, Chester EA, Newsom EE, et al. Randomized trial to improve laboratory safety monitoring of ongoing drug therapy in ambulatory patients. Pharmacotherapy 2006;26:619-26 DOI 10.1592/phco.26.5.619
7. Tjia J, Field TS, Garber LD, et al. Development and pilot testing of guidelines to monitor high-risk medications in the ambulatory setting. Am J Manag Care 2010;16:489-96
8. Hoigné R, Lawson DH, Weber E. Risk factors for adverse drug reactions-epidemiological approaches. Eur J Clin Pharm 1990;39:321-5
9. Physicians' Desk Reference. New York, NY: Thomson Reuters, 2010. www.pdr.net (accessed 2011 May 6).
10. Cohen J, Insel P. The Physicians' Desk Reference. Problems and possible improvements. Arch Intern Med 1996;156:1375-80. DOI 10.1001/archinte.156.13.1375
11. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235. DOI 10.1161/ CIRCULATIONAHA.105.167586
12. National Committee for Quality Assurance. HEDIS 2009: Healthcare effectiveness data & information set. Vol. 2, technical specifications. Washington, DC: National Committee for Quality Assurance, 2008.
13. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-86 DOI 10.1002/pds.1193
14. Raebel MA, Carroll NM, Andrade SE, et al. Monitoring of drugs with a narrow therapeutic range in ambulatory care. Am J Manag Care 2006; 12:268-74.
15. Raebel MA, Lyons EE, Chester EA, et al. Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. Arch Intern Med 2005;165:2395-401 DOI 10.1001/archinte.165.20.2395
16. 2000 Census of population and housing, summary population and housing characteristics PHC-1-1, Table 1. Age and sex. Washington, DC: United States Census Bureau 2002:2-3
17. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66 DOI 10.1001/jama.296.15.1858
18. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007;55(suppl 2):S373-82. DOI 10.1111/j.1532-5415.2007.01345.x
19. Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004;140:714-20.
20. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72 DOI 10.1001/jama.289.19.2560
21. Micromedex Healthcare Series. New York, NY: Thomson Reuters (Healthcare) Inc., 2010
22. Recommended laboratory monitoring for common medications. Pharmacist's Letter/Prescriber's Letter 2006;22:221250.
23. Liver function test scheduling. Pharmacist's Letter/Prescriber's Letter 2005;21:211210.
24. Yu DT, Seger DL, Lasser KE, et al. Impact of implementing alerts about medication black-box warnings in electronic health records. Pharmacoepidemiol Drug Saf 2011;20:192-202 DOI 10.1002/pds.2088
25. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65 DOI 10.1001/jama.282.15.1458
26. Leape LL, Weissman JS, Schneider EC, Piana RN, Gatsonis C, Epstein AM. Adherence to practice guidelines: the role of specialty society guidelines. Am Heart J 2003;145:19-26 DOI 10.1067/mhj.2003.3
27. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. JAMA 2004;292:2622-31 DOI 10.1001/jama.292.21.2622
28. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA 2004;292:2643-6. DOI 10.1001/jama.292.21.2643
29. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63:136-47 DOI 10.1111/j.1365-2125.2006.02698.x
30. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006;166:338-44 DOI 10.1001/archinte.166.3.338
31. Raebel M, Ross C, Xu S, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med 2010;25:326-33. DOI 10.1007/s11606-009-1228-x
32. Raebel MA, Carroll NM, Simon SR, et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm 2006;12:656-64.
33. Ryan C, O'Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. Ann Pharmacother 2009; 43:1239-44. DOI 10.1345/aph.1M157
34. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160:1741-8. DOI 10.1001/archinte.160.12.1741
35. Bickford CL, Spencer AP. Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm 2006; 12:254-9.
36. Fischer, SH, Tjia, J, Field, TS. The impact of health information technology interventions to improve medication laboratory monitoring for ambulatory patients: a systematic review. J Am Med Inform Assoc 2010; 17:631-6 DOI 10.1136/jamia.2009.000794